After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved.

Tirzepatide, the active ingredient in the diabetes and obesity medications Mounjaro and Zepbound, was declared in shortage in December 2022. The shortage has been attributed to increased demand as interest in GLP-1 medications has soared.

The Food and Drug Administration (FDA) confirmed in a statement Wednesday that the shortage is now considered to be resolved.

"FDA confirmed with the drug’s manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national........

© The Hill